MGD011, A CD19 x CD3 Dual-Affinity Retargeting Bi-specific Molecule Incorporating Extended Circulating Half-life for the Treatment of B-Cell Malignancies von Liu, Liqin, Lam, Chia-Ying K, Long, Vatana, Widjaja, Lusiana, Yang, Yinhua, Li, Hua, Jin, Linda, Burke, Steve, Gorlatov, Sergey, Brown, Jennifer, Alderson, Ralph, Lewis, Margaret D, Nordstrom, Jeffrey L, Koenig, Scott, Moore, Paul A, Johnson, Syd, Bonvini, Ezio

Volltext

Preclinical Development of MGC018, a Duocarmycin-based Antibody-drug Conjugate Targeting B7-H3 for Solid Cancer von Scribner, Juniper A, Brown, Jennifer G, Son, Thomas, Chiechi, Michael, Li, Pam, Sharma, Sharad, Li, Hua, De Costa, Anushka, Li, Ying, Chen, Yan, Easton, Ann, Yee-Toy, Nicholas C, Chen, Francine Z, Gorlatov, Sergey, Barat, Bhaswati, Huang, Ling, Wolff, Christina R, Hooley, Jeff, Hotaling, Tim E, Gaynutdinov, Timur, Ciccarone, Valentina, Tamura, James, Koenig, Scott, Moore, Paul A, Bonvini, Ezio, Loo, Deryk

Volltext

Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial von Sherry, Nicole, Dr, Hagopian, William, MD, Ludvigsson, Johnny, Prof, Jain, Sunil M, MD, Wahlen, Jack, MD, Ferry, Robert J, Prof, Bode, Bruce, MD, Aronoff, Stephen, MD, Holland, Christopher, MS, Carlin, David, PhD, King, Karen L, MS, Wilder, Ronald L, MD, Pillemer, Stanley, MD, Bonvini, Ezio, MD, Johnson, Syd, PhD, Stein, Kathryn E, PhD, Koenig, Scott, MD, Herold, Kevan C, Prof, Daifotis, Anastasia G, MD

Volltext

Development of MGD007, a gpA33 x CD3-Bispecific DART Protein for T-Cell Immunotherapy of Metastatic Colorectal Cancer von Moore, Paul A, Shah, Kalpana, Yang, Yinhua, Alderson, Ralph, Roberts, Penny, Long, Vatana, Liu, Daorong, Li, Jonathan C, Burke, Steve, Ciccarone, Valentina, Li, Hua, Fieger, Claudia B, Hooley, Jeff, Easton, Ann, Licea, Monica, Gorlatov, Sergey, King, Kathy L, Young, Peter, Adami, Arash, Loo, Deryk, Chichili, Gurunadh R, Liu, Liqin, Smith, Douglas H, Brown, Jennifer G, Chen, Francine Z, Koenig, Scott, Mather, Jennie, Bonvini, Ezio, Johnson, Syd

Volltext

Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trial von Aggarwal, Charu, Prawira, Amy, Antonia, Scott, Rahma, Osama, Tolcher, Anthony, Cohen, Roger B, Lou, Yanyan, Hauke, Ralph, Vogelzang, Nicholas, P Zandberg, Dan, Kalebasty, Arash Rezazadeh, Atkinson, Victoria, Adjei, Alex A, Seetharam, Mahesh, Birnbaum, Ariel, Weickhardt, Andrew, Ganju, Vinod, Joshua, Anthony M, Cavallo, Rosetta, Peng, Linda, Zhang, Xiaoyu, Kaul, Sanjeev, Baughman, Jan, Bonvini, Ezio, Moore, Paul A, Goldberg, Stacie M, Arnaldez, Fernanda I, Ferris, Robert L, Lakhani, Nehal J

Volltext

A humanized CD3ε-knock-in mouse model for pre-clinical testing of anti-human CD3 therapy von Crespo, Joel, Koh, Yi Ting, Hu, Ningjie, Moore, Paul A, Bonvini, Ezio, Glasebrook, Andrew L, Martin, Andrea P, Benschop, Robert J

Volltext

Development and Preliminary Clinical Activity of PD-1-Guided CTLA-4 Blocking Bispecific DART Molecule von Berezhnoy, Alexey, Sumrow, Bradley J., Stahl, Kurt, Shah, Kalpana, Liu, Daorong, Li, Jonathan, Hao, Su-Shin, De Costa, Anushka, Kaul, Sanjeev, Bendell, Johanna, Cote, Gregory M., Luke, Jason J., Sanborn, Rachel E., Sharma, Manish R., Chen, Francine, Li, Hua, Diedrich, Gundo, Bonvini, Ezio, Moore, Paul A.

Volltext

Antitumor activity of the investigational B7-H3 antibody-drug conjugate, vobramitamab duocarmazine, in preclinical models of neuroblastoma von Brignole, Chiara, Calarco, Enzo, Bensa, Veronica, Giusto, Elena, Perri, Patrizia, Ciampi, Eleonora, Corrias, Maria Valeria, Astigiano, Simonetta, Cilli, Michele, Loo, Derik, Bonvini, Ezio, Pastorino, Fabio, Ponzoni, Mirco

Volltext

Selective Blockade of Inhibitory Fcγ Receptor Enables Human Dendritic Cell Maturation with IL-12p70 Production and Immunity to Antibody-Coated Tumor Cells von Dhodapkar, Kavita M., Kaufman, Jacob L., Ehlers, Marc, Banerjee, Devi K., Bonvini, Ezio, Koenig, Scott, Steinman, Ralph M., Ravetch, Jeffrey V., Dhodapkar, Madhav V.

Volltext

Abstract 1533: IMGC936, a first-in-class ADAM9-targeting antibody-drug conjugate, demonstrates promising anti-tumor activity von Hicks, Stuart, Loo, Deryk, Sinkevicius, Kerstin, Scribner, Juniper, Barat, Bhaswati, Yoder, Nicholas, Espelin, Christopher, Themeles, Marian, Chen, Francine, Lucas, Jacquelynn, Brown, Jennifer, Matin, Bahar, Fuller, Megan, Lee, Jenny, Salomon, Paulin, Costoplus, Juliet, Yancey, Sadiqa, Diedrich, Gundo, Gorlatov, Sergey, Son, Thomas, Chiechi, Michael, Li, Pam, Spliedt, Michael, Ciccarone, Valentina, Hooley, Jeff, Gantt, Nadia, Tamura, James, Donahue, Kerry, Moore, Paul, Johnson, Syd, Chittenden, Thomas, Gregory, Richard, Bonvini, Ezio

Volltext

Isolation of cancer stem like cells from human adenosquamous carcinoma of the lung supports a monoclonal origin from a multipotential tissue stem cell von Mather, Jennie P, Roberts, Penelope E, Pan, Zhuangyu, Chen, Francine, Hooley, Jeffrey, Young, Peter, Xu, Xiaolin, Smith, Douglas H, Easton, Ann, Li, Panjing, Bonvini, Ezio, Koenig, Scott, Moore, Paul A

Volltext

Tailoring CD19xCD3-DART exposure enhances T-cells to eradication of B-cell neoplasms von Circosta, Paola, Elia, Angela Rita, Landra, Indira, Machiorlatti, Rodolfo, Todaro, Maria, Aliberti, Sabrina, Brusa, Davide, Deaglio, Silvia, Chiaretti, Sabina, Bruna, Riccardo, Gottardi, Daniela, Massaia, Massimo, Giacomo, Filomena Di, Guarini, Anna Rita, Foà, Robin, Kyriakides, Peter W., Bareja, Rohan, Elemento, Olivier, Chichili, Gurunadh R., Monteleone, Emanuele, Moore, Paul A., Johnson, Syd, Bonvini, Ezio, Cignetti, Alessandro, Inghirami, Giorgio

Volltext

682 Antibody-mediated blockade of interleukin-10 receptor-alpha promotes the activation of immune cells from in vitro dissociated tumor samples von Berezhnoy, Alexey, Shah, Kalpana, Liu, Daorong, Lung, Peter, Long, Vatana, Stahl, Kurt, Smith, Douglas, Chen, Francine, Li, Hua, Li, Jonathan, Alderson, Ralph, Ciccarone, Valentina, Tamura, James, Bonvini, Ezio, Diedrich, Gundo, Moore, Paul

Volltext

Intramolecular Regulation of Phospholipase C-γ1 by Its C-Terminal Src Homology 2 Domain von DeBell, Karen, Graham, Laurie, Reischl, Ilona, Serrano, Carmen, Bonvini, Ezio, Rellahan, Barbara

Volltext

CAR T Cells Targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors von Majzner, Robbie G, Theruvath, Johanna L, Nellan, Anandani, Heitzeneder, Sabine, Cui, Yongzhi, Mount, Christopher W, Rietberg, Skyler P, Linde, Miles H, Xu, Peng, Rota, Christopher, Sotillo, Elena, Labanieh, Louai, Lee, Daniel W, Orentas, Rimas J, Dimitrov, Dimiter S, Zhu, Zhongyu, Croix, Brad St, Delaidelli, Alberto, Sekunova, Alla, Bonvini, Ezio, Mitra, Siddhartha S, Quezado, Martha M, Majeti, Ravindra, Monje, Michelle, Sorensen, Poul H B, Maris, John M, Mackall, Crystal L

Volltext

Teplizumab Preserves C-Peptide in Recent-Onset Type 1 Diabetes von Hagopian, William, Ferry, Robert J., Sherry, Nicole, Carlin, David, Bonvini, Ezio, Johnson, Syd, Stein, Kathryn E., Koenig, Scott, Daifotis, Anastasia G., Herold, Kevan C., Ludvigsson, Johnny

Volltext

Targeting CD123 in acute myeloid leukemia using a T-cell–directed dual-affinity retargeting platform von Al-Hussaini, Muneera, Rettig, Michael P., Ritchey, Julie K., Karpova, Darja, Uy, Geoffrey L., Eissenberg, Linda G., Gao, Feng, Eades, William C., Bonvini, Ezio, Chichili, Gurunadh R., Moore, Paul A., Johnson, Syd, Collins, Lynne, DiPersio, John F.

Volltext

Teplizumab Preserves C-Peptide in Recent-Onset Type 1 Diabetes: Two-Year Results From the Randomized, Placebo-Controlled Protégé Trial von HAGOPIAN, William, FERRY, Robert J, LUDVIGSSON, Johnny, SHERRY, Nicole, CARLIN, David, BONVINI, Ezio, JOHNSON, Syd, STEIN, Kathryn E, KOENIG, Scott, DAIFOTIS, Anastasia G, HEROLD, Kevan C

Volltext

Combinatorial Anti-Tumor Activity in Animal Models of a Novel CD123 x CD3 Bispecific Dart® Molecule (MGD024) with Cytarabine, Venetoclax or Azacitidine Supports Combination Therapy... von Alderson, Ralph F., Huang, Ling, Zhang, Xiaoyu, Li, Haiquan, Kaufman, Thomas, Diedrich, Gundo, Moore, Paul, Bonvini, Ezio

Volltext

Abstract 1555: Enhanced HER2-dependent immune activation by margetuximab, an investigational Fc-engineered anti-HER2 mAb, supports combination with checkpoint blockade von Zhang, Xiaoyu, Li, Haiquan, Yang, Yinhua, Xu, Qihong, Kaufman, Tom, Smith, Doug, Nordstrom, Jeffrey, Bonvini, Ezio, Moore, Paul

Volltext